Key Events This Week
21 Sep: Intraday high surge with 5.17% gain to Rs.2,437
21 Sep: Sharp open interest rise by 34.4% signalling bullish market momentum
22 Sep: Technical momentum shifts with 4.83% price gain amid mixed signals
25 Sep: Week closes at Rs.2,475.45, up 6.79% vs Sensex down 0.76%
21 September 2026: Intraday Surge and Open Interest Spike
Mankind Pharma Ltd began the week on a strong note, recording a notable intraday high of Rs.2,437 on 21 September 2026, representing a 5.17% surge from the previous close. The stock closed at Rs.2,429.85, up 4.83% for the day, significantly outperforming the Sensex which rose a modest 0.46% to 35,787.64. This robust price action reflected strong buying interest and momentum within the pharmaceutical mid-cap.
Simultaneously, the derivatives market saw a sharp increase in open interest, rising 34.4% to 28,326 contracts. This surge accompanied a daily volume of 1,26,433 contracts and a combined notional value of nearly ₹29,985.3 lakhs, indicating fresh bullish positioning by traders. The futures and options activity suggested increased confidence in the stock’s upward trajectory, supported by a 5.62% price gain intraday and sustained volume growth.
Technically, the stock was trading above its 5-day, 20-day, 100-day, and 200-day moving averages, signalling short- to long-term strength, although it remained below the 50-day moving average, indicating some resistance at intermediate levels. The narrow intraday trading range suggested consolidation near recent highs, often a precursor to further directional moves.
Our latest weekly pick is out! This Large Cap from Steel/Sponge Iron/Pig Iron delivered with target price and complete analysis. See what makes this week's selection special!
- - Latest weekly selection
- - Target price delivered
- - Large Cap special pick
22 September 2026: Technical Momentum Shifts Amid Mixed Signals
On 22 September, Mankind Pharma continued its upward trajectory, closing at Rs.2,479.40, up 2.04% from the previous day’s close. The stock traded within a range of Rs.2,302.30 to Rs.2,451.00, approaching its 52-week high of Rs.2,670.00. This price action reflected renewed investor interest and a potential technical breakout after a period of consolidation.
Despite the positive price movement, technical indicators presented a mixed picture. The Moving Average Convergence Divergence (MACD) remained mildly bearish on weekly and monthly charts, while daily moving averages turned bullish. The Relative Strength Index (RSI) hovered in a neutral zone, indicating neither overbought nor oversold conditions. Bollinger Bands showed sideways movement on weekly charts but a bullish expansion on monthly charts, suggesting growing volatility with an upward bias.
The Know Sure Thing (KST) indicator and Dow Theory assessments also reflected this cautious optimism, with mildly bearish signals on longer-term charts contrasting with short-term bullish trends. On-balance volume (OBV) showed no clear confirmation, indicating volume had yet to decisively support the price gains.
MarketsMOJO assigned Mankind Pharma a Mojo Score of 65.0, categorised as a Hold rating, reflecting the balanced technical signals and the need for further confirmation before a stronger bullish stance can be adopted.
23 to 25 September 2026: Consolidation and Week Close
Following the strong gains earlier in the week, Mankind Pharma experienced some consolidation. On 23 September, the stock dipped slightly by 0.68% to Rs.2,462.50 on relatively low volume, while the Sensex gained 0.56%. The stock rebounded on 24 September, rising 0.51% to Rs.2,475.00 despite a sharp Sensex decline of 1.62%, demonstrating relative resilience amid broader market weakness.
On the final trading day, 25 September, Mankind Pharma closed marginally higher by 0.02% at Rs.2,475.45, while the Sensex gained 0.18%. The stock’s ability to hold near its weekly highs amid volatile market conditions underscored its relative strength and investor interest.
Why settle for Mankind Pharma Ltd? SwitchER evaluates this mid-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Weekly Price Performance: Mankind Pharma vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-09-21 | Rs.2,429.85 | +4.83% | 35,787.64 | +0.46% |
| 2026-09-22 | Rs.2,479.40 | +2.04% | 35,672.04 | -0.32% |
| 2026-09-23 | Rs.2,462.50 | -0.68% | 35,870.78 | +0.56% |
| 2026-09-24 | Rs.2,475.00 | +0.51% | 35,291.38 | -1.62% |
| 2026-09-25 | Rs.2,475.45 | +0.02% | 35,353.29 | +0.18% |
Key Takeaways
Strong Weekly Outperformance: Mankind Pharma’s 6.79% weekly gain contrasted sharply with the Sensex’s 0.76% decline, highlighting the stock’s resilience and relative strength amid a volatile market environment.
Derivatives Market Activity: The 34.4% surge in open interest on 21 September signalled fresh bullish bets and increased investor participation, supported by robust volume and notional values in futures and options segments.
Technical Momentum Shift: The transition from mildly bearish to mildly bullish technical indicators, including daily moving averages and monthly Bollinger Bands, suggests improving momentum, though mixed signals from MACD, KST, and volume metrics warrant cautious monitoring.
Hold Rating Reflects Balanced View: The Mojo Score of 65.0 and Hold grade reflect a balanced assessment, recognising the stock’s recent gains and technical improvements while acknowledging the need for further confirmation amid sector volatility.
Conclusion
Mankind Pharma Ltd’s week was characterised by strong price gains, significant derivatives market activity, and a cautious shift in technical momentum. The stock’s 6.79% weekly rise and outperformance of the Sensex underscore its appeal within the pharmaceutical mid-cap space. However, mixed technical signals and a Hold rating from MarketsMOJO suggest that investors should remain vigilant and await clearer confirmation of sustained momentum before adopting a more aggressive stance. The evolving market dynamics and sector-specific factors will be critical to watch in the coming weeks as Mankind Pharma navigates this pivotal phase.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
